BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 25065940)

  • 1. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
    Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.
    Brizzi A; Brizzi V; Cascio MG; Corelli F; Guida F; Ligresti A; Maione S; Martinelli A; Pasquini S; Tuccinardi T; Di Marzo V
    J Med Chem; 2009 Apr; 52(8):2506-14. PubMed ID: 19331413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
    Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
    Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
    Pasquini S; Botta L; Semeraro T; Mugnaini C; Ligresti A; Palazzo E; Maione S; Di Marzo V; Corelli F
    J Med Chem; 2008 Aug; 51(16):5075-84. PubMed ID: 18680276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
    Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
    Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.
    Brizzi A; Aiello F; Boccella S; Cascio MG; De Petrocellis L; Frosini M; Gado F; Ligresti A; Luongo L; Marini P; Mugnaini C; Pessina F; Corelli F; Maione S; Manera C; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2020 Jun; 28(11):115513. PubMed ID: 32340793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
    Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
    Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.
    Pasquini S; Mugnaini C; Ligresti A; Tafi A; Brogi S; Falciani C; Pedani V; Pesco N; Guida F; Luongo L; Varani K; Borea PA; Maione S; Di Marzo V; Corelli F
    J Med Chem; 2012 Jun; 55(11):5391-402. PubMed ID: 22548457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
    Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
    J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
    Brizzi A; Cascio MG; Frosini M; Ligresti A; Aiello F; Biotti I; Brizzi V; Pertwee RG; Corelli F; Di Marzo V
    J Med Chem; 2011 Dec; 54(24):8278-88. PubMed ID: 22044209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.
    Pasquini S; Ligresti A; Mugnaini C; Semeraro T; Cicione L; De Rosa M; Guida F; Luongo L; De Chiaro M; Cascio MG; Bolognini D; Marini P; Pertwee R; Maione S; Di Marzo V; Corelli F
    J Med Chem; 2010 Aug; 53(16):5915-28. PubMed ID: 20718492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
    Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
    Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.
    Presley CS; Mustafa SM; Abidi AH; Moore BM
    Bioorg Med Chem; 2015 Sep; 23(17):5390-401. PubMed ID: 26275680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
    J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
    Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
    J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
    Showalter VM; Compton DR; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
    Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
    Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
    Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.